## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.96 indicates fundamental undervaluation. Quality metrics strong (ROE 96%, ROA 18%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($1011.69)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls**
- Source: Finviz | 20251218T230219 | Bullish | Relevance: 100%
- Eli Lilly (LLY) recently received support from top financial institutions, with Daiwa upgrading the stock to Buy and Goldman Sachs raising its price target. This positive sentiment is fueled by the strong performance of Eli Lilly's weight-loss drug pipeline, particularly retatrutide, which showed significant weight reduction and additional health benefits in clinical trials. The company anticipates further data release for retatrutide in 2026, building on its success in the GLP-1 therapy market.

**2. Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound**
- Source: CNBC | 20251218T121006 | Bullish | Relevance: 100%
- Eli Lilly announced that its obesity pill, orforglipron, helped patients maintain the majority of their weight loss after switching from injectable drugs like Wegovy and Zepbound in a late-stage trial. The company has filed for FDA approval for the daily GLP-1 pill, suggesting it could be a valuable needle-free maintenance option for individuals seeking to preserve weight loss without long-term injections. While potentially causing less overall weight loss than injectables, the pill's role as a maintenance treatment could significantly impact the GLP-1 market.

**3. Eli Lilly & Co. cuts price of popular diabetes and weight-loss drugs in Canada**
- Source: The Globe and Mail | 20251218T040755 | Neutral | Relevance: 100%
- Eli Lilly & Co. is significantly reducing the prices of its diabetes and weight-loss drugs, Mounjaro and Zepbound, in Canada by 20% or more, effective December 29th. This move comes in anticipation of new federal pricing regulations and the imminent entry of generic Ozempic into the Canadian market. This strategic cut aims to realign pricing and compete in a rapidly evolving pharmaceutical landscape.

**4. Market Chatter: Eli Lilly and Company to Reduce Prices of Its Diabetes, Weight-Loss Drugs in Canada by 20% or More**
- Source: 富途牛牛 | 20251218T141017 | Somewhat-Bearish | Relevance: 100%
- Eli Lilly and Company is reportedly planning to reduce the prices of its diabetes and weight-loss drugs in Canada by 20% or more. This news comes as Unity Software (U.US) also reported its fourth-quarter financial results, with revenue beating estimates. The article briefly mentions financial results for Unity Software ($U) as well.

**5. Ransom Advisory Ltd Increases Stock Position in Eli Lilly and Company $LLY**
- Source: MarketBeat | 20251218T120829 | Bullish | Relevance: 100%
- Ransom Advisory Ltd significantly increased its stake in Eli Lilly and Company (NYSE:LLY) by 112.9% in the third quarter, bringing its total holdings to 2,451 shares valued at $1.87 million. The pharmaceutical giant exceeded quarterly expectations with $7.02 EPS and $17.6 billion in revenue, also providing strong FY2025 guidance. Analysts maintain a largely bullish outlook on Eli Lilly, reflected in numerous "Strong Buy" and "Buy" ratings and an average target price of $1,141.73.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $1268 | $1286 | -1% |
| 2025-12-10 | Wells Fargo | $1200 | $1100 | +9% |
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | main | Buy |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($1.49M) |
| Sells | 28 ($18559.12M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Heavy insider selling: $18559M sold (28 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 5 raises (avg +12%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 32.9x attractive for 38% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Revenue growth strong at 20% YoY. Analyst sentiment positive (5 raises, avg +12%). Insider selling cluster ($18559.1M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $960.5B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 32.9 |
| Current P/E | 45.3 |
| YoY Growth | 37.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at 2.2% (minimal 5-day change). Below STRENGTH zone by 1.8pp (needs >4.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-2.29), momentum weakening. OFD pattern: +SLH (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.22% (CS: 71) | Neutral |
| RSI_14 | 63.8 | Neutral |
| MACD Histogram | -2.29 | Bearish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.121x | Above |
| vs SMA200 | 1.309x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $1070.87
- **Stop Loss:** $1011.69 (5.5% risk)
- **Target:** $1189.23 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $21,417.40
- **Portfolio %:** 21.42%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-05 (Est: $7.18)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*